Petros Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.88
- Today's High:
- $2
- Open Price:
- $1.9
- 52W Low:
- $0.917
- 52W High:
- $9.54
- Prev. Close:
- $1.88
- Volume:
- 13174
Company Statistics
- Market Cap.:
- $5.16 million
- Book Value:
- 6.107
- Revenue TTM:
- $3.85 million
- Operating Margin TTM:
- -365.63%
- Gross Profit TTM:
- $6.21 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -22.07%
- Return on Equity TTM:
- -93.23%
Company Profile
Petros Pharmaceuticals Inc had its IPO on 2020-12-02 under the ticker symbol PTPI.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Petros Pharmaceuticals Inc has a staff strength of 24 employees.
Stock update
Shares of Petros Pharmaceuticals Inc opened at $1.9 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.88 - $2, and closed at $1.95.
This is a +3.72% increase from the previous day's closing price.
A total volume of 13,174 shares were traded at the close of the day’s session.
In the last one week, shares of Petros Pharmaceuticals Inc have slipped by -22%.
Petros Pharmaceuticals Inc's Key Ratios
Petros Pharmaceuticals Inc has a market cap of $5.16 million, indicating a price to book ratio of 0.2331 and a price to sales ratio of 1.0146.
In the last 12-months Petros Pharmaceuticals Inc’s revenue was $3.85 million with a gross profit of $6.21 million and an EBITDA of $-9954502. The EBITDA ratio measures Petros Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Petros Pharmaceuticals Inc’s operating margin was -365.63% while its return on assets stood at -22.07% with a return of equity of -93.23%.
In Q2, Petros Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 52.4%.
Petros Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-10.16 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Petros Pharmaceuticals Inc’s profitability.
Petros Pharmaceuticals Inc stock is trading at a EV to sales ratio of 0.8335 and a EV to EBITDA ratio of -0.2101. Its price to sales ratio in the trailing 12-months stood at 1.0146.
Petros Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $28.73 million
- Total Liabilities
- $7.97 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Petros Pharmaceuticals Inc ended 2024 with $28.73 million in total assets and $0 in total liabilities. Its intangible assets were valued at $28.73 million while shareholder equity stood at $12.94 million.
Petros Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $7.97 million in other current liabilities, 211.00 in common stock, $-94658223.00 in retained earnings and $-10585407996.00 in goodwill. Its cash balance stood at $7.38 million and cash and short-term investments were $7.38 million. The company’s total short-term debt was $1,122,619 while long-term debt stood at $7.63 million.
Petros Pharmaceuticals Inc’s total current assets stands at $13.15 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $2.58 million compared to accounts payable of $1.78 million and inventory worth $2.18 million.
In 2024, Petros Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Petros Pharmaceuticals Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.95
- 52-Week High
- $9.54
- 52-Week Low
- $0.917
- Analyst Target Price
- $
Petros Pharmaceuticals Inc stock is currently trading at $1.95 per share. It touched a 52-week high of $9.54 and a 52-week low of $9.54. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $3.02 and 200-day moving average was $2.8 The short ratio stood at 0.87 indicating a short percent outstanding of 0%.
Around 3265.7% of the company’s stock are held by insiders while 195.1% are held by institutions.
Frequently Asked Questions About Petros Pharmaceuticals Inc
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men’s health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie’s disease. The company offers men’s health products, including vacuum erection devices, PreBoost, VenoSeal, penile injections, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.